<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>prostate cancer treatment &#8211; BIOENGINEER.ORG</title>
	<atom:link href="https://bioengineer.org/tag/prostate-cancer-treatment/feed/" rel="self" type="application/rss+xml" />
	<link>https://bioengineer.org</link>
	<description>Bioengineering</description>
	<lastBuildDate>Wed, 15 Oct 2025 16:39:47 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://bioengineer.org/wp-content/uploads/2019/09/cropped-bioengineering-32x32.png</url>
	<title>prostate cancer treatment &#8211; BIOENGINEER.ORG</title>
	<link>https://bioengineer.org</link>
	<width>32</width>
	<height>32</height>
</image> 
<site xmlns="com-wordpress:feed-additions:1">72741379</site>	<item>
		<title>High-Speed Whole-Body SPECT Technology Advances Tracking of Tumor Evolution to Enhance Prostate Cancer Treatment</title>
		<link>https://bioengineer.org/high-speed-whole-body-spect-technology-advances-tracking-of-tumor-evolution-to-enhance-prostate-cancer-treatment/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Wed, 15 Oct 2025 16:39:31 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[**Tags:** High-Speed SPECT imaging]]></category>
		<category><![CDATA[177Lu-PSMA therapy]]></category>
		<category><![CDATA[prostate cancer treatment]]></category>
		<category><![CDATA[tumor evolution tracking]]></category>
		<guid isPermaLink="false">https://bioengineer.org/high-speed-whole-body-spect-technology-advances-tracking-of-tumor-evolution-to-enhance-prostate-cancer-treatment/</guid>

					<description><![CDATA[image: Figure 2: Maximum-intensity projection images from [68Ga]Ga-PSMA and [18F]-FDG PET before treatment, and [177Lu]Lu SPECT displayed without and with (red) segmentation with SUV of >3 in 74-y-old mCRPC patient. [177Lu]Lu-PSMA therapy was stopped at third injection despite dramatic decrease in PSA because of lack of favorable impact on symptoms and worsening clinical condition, and patient died 6 months [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">281545</post-id>	</item>
		<item>
		<title>Groundbreaking Genomic Test Forecasts Hormone Therapy Benefits in Recurrent Prostate Cancer Treatment</title>
		<link>https://bioengineer.org/groundbreaking-genomic-test-forecasts-hormone-therapy-benefits-in-recurrent-prostate-cancer-treatment/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Sun, 28 Sep 2025 20:18:54 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[BALANCE trial]]></category>
		<category><![CDATA[genomic biomarker]]></category>
		<category><![CDATA[hormone therapy response]]></category>
		<category><![CDATA[personalized oncology]]></category>
		<category><![CDATA[prostate cancer treatment]]></category>
		<guid isPermaLink="false">https://bioengineer.org/groundbreaking-genomic-test-forecasts-hormone-therapy-benefits-in-recurrent-prostate-cancer-treatment/</guid>

					<description><![CDATA[A groundbreaking clinical study has unveiled a transformative biomarker that could revolutionize treatment strategies for recurrent prostate cancer patients post-surgery. This pivotal randomized trial reveals that a genomic tumor profiling test can precisely predict which patients stand to gain from adjunct hormone therapy following radiation, establishing the first predictive biomarker in the post-prostatectomy landscape. The [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">272999</post-id>	</item>
		<item>
		<title>Research Validates Safety and Effectiveness of Increased Daily Radiation Doses for Early-Stage Prostate Cancer</title>
		<link>https://bioengineer.org/research-validates-safety-and-effectiveness-of-increased-daily-radiation-doses-for-early-stage-prostate-cancer/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Tue, 18 Mar 2025 18:37:10 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[clinical trial outcomes]]></category>
		<category><![CDATA[early-stage prostate cancer]]></category>
		<category><![CDATA[hypofractionated radiotherapy]]></category>
		<category><![CDATA[prostate cancer treatment]]></category>
		<category><![CDATA[radiation therapy safety]]></category>
		<guid isPermaLink="false">https://bioengineer.org/research-validates-safety-and-effectiveness-of-increased-daily-radiation-doses-for-early-stage-prostate-cancer/</guid>

					<description><![CDATA[A recent seminal study conducted by UCLA Health Jonsson Comprehensive Cancer Center researchers has illuminated a significant breakthrough in the treatment of prostate cancer. This investigation offers compelling evidence supporting the use of a condensed radiation therapy protocol, which could revolutionize patient care in oncology. Specifically, the research highlights the efficacy and safety of isodose [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">238690</post-id>	</item>
		<item>
		<title>Breakthrough Lipid Nanoparticle Therapy Shows Promise in Halting Tumor Growth and Reinstituting Tumor Suppression</title>
		<link>https://bioengineer.org/breakthrough-lipid-nanoparticle-therapy-shows-promise-in-halting-tumor-growth-and-reinstituting-tumor-suppression/</link>
		
		<dc:creator><![CDATA[Bioengineer]]></dc:creator>
		<pubDate>Thu, 09 Jan 2025 21:11:14 +0000</pubDate>
				<category><![CDATA[Cancer]]></category>
		<category><![CDATA[lipid nanoparticle therapy]]></category>
		<category><![CDATA[mRNA siRNA delivery]]></category>
		<category><![CDATA[nanomedicine cancer research]]></category>
		<category><![CDATA[prostate cancer treatment]]></category>
		<category><![CDATA[tumor suppression mechanisms]]></category>
		<guid isPermaLink="false">https://bioengineer.org/breakthrough-lipid-nanoparticle-therapy-shows-promise-in-halting-tumor-growth-and-reinstituting-tumor-suppression/</guid>

					<description><![CDATA[Novel mRNA and siRNA Delivery System Shows Promise for Prostate Cancer Treatment Groundbreaking research from scientists at the Center for Nanomedicine and the Department of Anesthesiology, Perioperative, and Pain Medicine at Brigham and Women’s Hospital highlights a powerful new approach for combating prostate cancer. This study, led by Yang Zhang, PhD, and Jinjun Shi, PhD, [&#8230;]]]></description>
		
		
		
		<post-id xmlns="com-wordpress:feed-additions:1">233498</post-id>	</item>
	</channel>
</rss>
